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Background and objectives: African-American (AA) children with focal segmental
glomerulosclerosis (FSGS) have later onset disease that progresses more rapidly than in
non-AA children. It is unclear how APOL1 genotypes contribute to kidney disease risk,
progression, and cardiovascular morbidity in children.
Design, setting, participants, and measurements: We examined the prevalence of
APOL1 genotypes and associated cardiovascular phenotypes among children with FSGS
in the Chronic Kidney Disease in Children (CKiD) study; an ongoing multicenter prospective cohort study of children aged 1–16 years with mild to moderate kidney disease.
results: A total of 140 AA children in the CKiD study were genotyped. High risk (HR)
APOL1 genotypes were present in 24% of AA children (33/140) and were associated
with FSGS, p < 0.001. FSGS was the most common cause of glomerular disease in
children with HR APOL1 (89%; 25/28). Of 32 AA children with FSGS, 25 (78%) had HR
APOL1. Compared to children with low risk APOL1 and FSGS (comprising 36 non-AA
and 7 AA), children with HR APOL1 developed FSGS at a later age, 12.0 (IQR: 9.5,
12.5) vs. 5.5 (2.5, 11.5) years, p = 0.004, had a higher prevalence of uncontrolled
hypertension (52 vs. 33%, p = 0.13), left ventricular hypertrophy (LVH) (53 vs. 12%,
p < 0.01), C-reactive protein > 3 mg/l (33 vs. 15%, p = 0.12), and obesity (48 vs. 19%,
p = 0.01). There were no differences in glomerular filtration rate, hemoglobin, iPTH, or
calcium–phosphate product.
conclusion: AA children with HR APOL1 genotype and FSGS have increase prevalence
of obesity and LVH despite a later age of FSGS onset, while adjusting for socioeconomic
status. Treatment of obesity may be an important component of chronic kidney disease
and LVH management in this population.
Keywords: cardiovascular, left ventricular hypertrophy, chronic renal disease, FSGS, children
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INTRODUCTION

Clinical and Laboratory Testing

All clinical and laboratory data in the analysis were based on the
first available observation, either at study entry or 6 months after,
and were categorized by indicators of renal, cardiovascular, and
metabolic health. Echocardiography data were collected 1 year
after study entry according to study protocol. Race, sociodemographic, and therapy use were self or parental reported.

African-Americans (AA) have higher rates of hypertension
(HTN) and kidney disease compared to Americans of European
descent (1). In adults of African descent, the presence of high
risk (HR) APOL1 genotype (characterized by the presence of two
risk alleles, defined as G1/G1 homozygotes, G2/G2 homozygotes,
and G1/G2 compound heterozygotes), preferentially selected by
the process of evolution, was found to be associated with nondiabetic or “hypertension-attributed” end-stage renal disease
(ESRD), idiopathic focal segmental glomerulosclerosis (FSGS),
and HIV-associated nephropathy (2–5). The role of APOL1 in the
adult cardiovascular phenotype is still controversial with some
recent findings, suggesting that APOL1 variants could contribute to atherosclerotic cardiovascular risk, indicating a genetic
component to cardiovascular health disparities among adults
of African ancestry (6). While studies in adult AA populations
demonstrated strong recessive association of APOL1 G1 and G2
genetic variants with glomerular and vascular disease progression (7), there is limited information on its role in children with
chronic kidney disease (CKD), particularly for cardiovascular
comorbidities. In NIH FSGS cohort study and in the FSGSClinical Trial (FSGS-CT), both of which included children and
adults, HR APOL1 genotype was present in 72% of self-identified
AA subjects (8).
Up to 63% of children with early stages of CKD present
with arterial HTN (9). In addition to being common, HTN is
associated with a greater rate of decline in kidney function and
is a known risk of development of ESRD (10). Furthermore,
in Chronic Kidney Disease in Children (CKiD), a population
with mild to moderate CKD, a high overall prevalence (53%) of
systolic HTN was observed (11). Presence of HTN in children
with CKD has also been associated with cardiovascular morbidity and development of left ventricular hypertrophy (LVH) (12).
LVH is common among hypertensive adults and children with
CKD and is more common among AA than in whites (13, 14).
While a previous report of two pediatric cohorts representing
children with CKD (CKiD) and nephrotic syndrome (Nephrotic
Syndrome Study Network; NEPTUNE) showed similar APOL1
characteristics in terms of FSGS diagnosis and disease progression (15), the association of APOL1 and cardiovascular
comorbidities in the presence of CKD has not been explored.
The purpose of this study was to extend previous findings (15),
to characterize the distribution of APOL1 risk alleles in the
CKiD cohort and, by comparing children with an underlying
FSGS cause of CKD, to describe the prevalence of cardiorenal
phenotypes and markers of disease severity associated with the
HR APOL1 genotype.

Genetic Testing

DNA was obtained from National Institute of Diabetes and
Digestive and Kidney Disease (NIDDK) genetics repository of
immortalized lymphocyte cell lines based on a sample of whole
blood taken at the 6-month-old study visit among those who
consented to genetic testing. APOL1 variants G1 (rs73885319,
S342G and rs60945101, I384M) and G2 (rs71785313, NY deletion) were genotyped.
The number of kidney risk alleles defined APOL1 risk
groups: low risk (LR) was defined by 0 or 1 risk allele (G0/G0
homozygous, or G1/G0 and G2/G0 heterozygous), and HR was
defined by 2 risk alleles (G1/G1 and G2/G2 homozygous, or G1/
G2 compound heterozygous), where G0 represents the ancestral
alleles at both rs73885319 and rs71785313 sites.
Indicators of renal health included glomerular filtration rate
(GFR) measured by plasma disappearance of iohexol or estimated
by CKiD-developed equations based on serum creatinine, cystatin C, and BUN, when iohexol GFR was not available. Proteinuria
was assessed as first morning urine protein (milligrams)/creatinine (milligrams) ratio (uPCR).
Indicators of cardiovascular health included the average of
three in-clinic measurements of blood pressure and left ventricular mass index (LVMI in g/m2.7) as measured by echocardiography. Uncontrolled HTN was defined as systolic blood pressure
(SBP) or diastolic blood pressure (DBP) ≥95th percentile for age,
sex, height according to the fourth report (17). LVH was defined
as LVMI ≥ age- and sex-specific 95th percentile based on the
normal population (18). All data were measured and defined by
the CKiD study protocol, as described previously (11, 16, 19).
Indicators of metabolic health included total, HDL, and LDL
cholesterol (milligrams per deciliter), triglycerides (milligrams
per deciliter) with age- and sex-defined categorical definitions
for abnormally high total cholesterol, low HDL, and high LDL
cholesterol, based on the normal population. Hemoglobin (grams
per deciliter), calcium (milligrams per deciliter), phosphate (milligrams per deciliter), and calcium × phosphate product were
measured. Hemoglobin was categorized by anemia status based
on age- and sex-defined levels of the normal population, and
phosphate levels were categorized as high based on age-defined
levels of the normal population. Intact parathyroid hormone
(iPTH) and C-reactive protein (CRP) were also measured (19),
with high sensitivity CRP primarily used (n = 47) and when
missing, informed by wide-range CRP data (n = 18; missing both
n = 3). High CRP was defined as CRP > 3 mg/l.
The CKiD Study protocol was approved by the institutional
review boards at the participating institutions, and all subjects
gave informed assent or consent. Genetic testing was approved
by the NIDDK Institutional Review Board.

MATERIALS AND METHODS
Subjects

The study population comprised of children enrolled in the
CKiD Study, an ongoing multicenter prospective cohort study
of children aged 1–16 years with mild to moderate kidney
disease (16).
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Statistical Analyses

RESULTS

Since 89% of children with the HR APOL1 profile had FSGS, the
appropriate comparison group to determine differences related
to APOL1 were children with LR APOL1 genotype and FSGS.
Fisher’s exact test for categorical variables and the Wilcoxon
rank-sum test for continuous variables were used to compare
univariate differences by APOL1 risk status among those with a
diagnosis of FSGS.
Since lower socioeconomic status (SES) was associated with
AA race in this North American cohort, and low SES is associated
with disease progression (20), SES is a potential confounder as the
exposure groups largely differ by race. To adjust for confounding due to SES, we used inverse probability of exposure weights
(IPWs) (21, 22). The IPWs were generated from a logistic regression model with HR APOL1 as the outcome and variables related
to SES as the predictors: income less than $36,000, maternal
education less than college, the presence of any public insurance and missing at least one dose of antihypertensive therapy
in the past 7 days (self-reported). The inverse of the predicted
probability of observed exposure was stabilized to the marginal
probability of each group (for HR APOL1: 25/68 = 0.37; and for
LR APOL1: 43/68 = 0.63). Selected cardiovascular, metabolic,
inflammatory, and other risk factors were compared to exposure
group in adjusted analyses using weighting by IPWs in logistic
regression models to obtain prevalence odds ratio comparing the
HR APOL1 group to the LR APOL1 group. The outcomes were
obesity, high LDL cholesterol, uncontrolled HTN, LVH, and
CRP > 3 mg/l. Multiple imputation was used to account for missing data, and the results are presented unadjusted (univariately,
with imputation where applicable) and adjusted to account for
the effect of confounding by SES.

A total of 891 children were enrolled in CKiD, of whom 199 (22%)
were AA; Figure 1 presents the distributions of APOL1 genotypes
and CKD diagnoses by race. Among 140 genotyped AA children,
HR APOL1 status was present in 33 (24%), and among these
33 individuals 28 (85%) had an underlying glomerular cause of
CKD, whereas only 5/33 (6%) had a non-glomerular cause of
CKD, p < 0.001. Of those 28 subjects with HR APOL1 status and
a glomerular disease, 25/28 (89%) had a diagnosis of FSGS. In
contrast, among 191 non-AA children with a glomerular CKD
cause, only 36 (19%) had an FSGS diagnosis, p < 0.001. Of the
28 AA children with LR APOL1 status (defined as presence of 0
or 1 risk allele), and glomerular CKD, 7 (25%) had a diagnosis
of FSGS (difference between HR and LR APOL1 AA, p < 0.001).
APOL1 genotyping was not performed in 59 children: 20 did not
consent to genetic testing, 19 dropped out of the study prior to
sample collections, 9 were not measured due to missing samples,
and 11 samples became available only after genotyping had been
completed. Of these 59 children, 47% had a glomerular cause of
CKD; 39% of these had a diagnosis of FSGS. The similar proportions of glomerular diagnoses and FSGS among AA LR APOL1
and non-AA LR APOL1 children (i.e., 25 and 19%, respectively)
suggest potentially similar pathologic mechanisms and were
distinct from the distributions observed among AA children with
HR APOL1. The proportion (47%) of FSGS diagnoses among
children with unmeasured APOL1 status is intermediate between
that observed among those with HR (85%) and LR (25%), suggesting that this group with unmeasured genotypes comprises
both HR and LR profiles. A total of 37 non-AA children were
genotyped, and all were identified as having LR APOL1 status

FIGURE 1 | Distribution of CKiD children by race [African-American (AA) vs. non-African-American (non-AA)], APOL1 genotypes, and CKD diagnoses
[glomerular disease (Glom), non-glomerular disease (Non-Glom), focal segmental glomerulosclerosis (FSGS)] All genotyped non-AA (N = 37) were
found to have LR APOL1 status, providing a justification for classifying non-AA children as low risk.
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(36 had 0 risk alleles and 1 harbored 1 risk allele). This provided
justification for classifying non-AA children as LR. A full list of
diagnoses by race and APOL1 status is provided in Table S1 in
Supplementary Material.
We compared the prevalence of renal and cardiovascular risk
factors by APOL1 status and AA race within FSGS diagnosis group
(n = 68). Since there were only seven subjects with LR APOL1 and
AA race, we pooled both AA (n = 7) and non-AA (n = 36) children as the reference population for statistical comparison with
AA children with HR APOL1 and FSGS (n = 25). Table 1 presents
the clinical, sociodemographic, and renal characteristics among
those with FSGS, stratified by race and APOL1 risk status. There
were similar proportions of boys and despite similar ages at study
entry, those with HR APOL1 were significantly taller (p = 0.003)
and heavier (p < 0.001), compared to children with LR APOL1.

This was reflected in the height and weight percentiles standardized to age and gender (i.e., normal, median height, and weight
percentiles are equal to 50): those with HR APOL1 had a median
height and weight percentiles significantly higher as compared
to those with LR APOL1, p = 0.033 and p < 0.001, respectively.
Body mass index (BMI) was significantly higher among the HR
APOL1 children (p < 0.001), and this group had a much higher
proportion of obesity (BMI > 85th percentile adjusted for age
and gender; 48 vs. 19%, p = 0.01). Consistent with previously
published reports (15), children with HR APOL1 had a higher
prevalence of premature birth than children with LR APOL1 (29
vs. 5%, p = 0.011), but this difference was not observed for low
birth weight or small for gestational age.
To account for the potential confounding effects of SES factors
related to race, inverse probability weights were used to adjust

TABLE 1 | Descriptive statistics of sociodemographic, renal health, and therapy use among children with FSGS, by race and APOL1 risk status
(LR, low risk vs. HR, high risk; non-AA, non-African-American; AA, African-American), in the CKiD study (n = 68), median (IQR), n (%); p-values based on
Fisher’s exact test or Wilcoxon rank-sum test.
Variable

Non-AA APOL1 LR
n = 36

AA APOL1 LR
n=7

Pooled APOL1 LR
n = 43

APOL1 HR
n = 25

p-Value
(pooled LR vs. HR)

21 (58%)
0
13.8 [9.6, 15.6]
7 (21%)
2 (6%)
7 (23%)
10 (29%)

4 (57%)
7 (100%)
15.0 [8.2, 16.5]
1 (17%)
0 (0%)
2 (33%)
2 (29%)

25 (58%)
7 (16%)
14.2 [9.5, 15.8]
8 (21%)
2 (5%)
9 (24%)
12 (29%)

11 (44%)
25 (100%)
14.8 [13.0, 15.5]
8 (33%)
7 (29%)
7 (30%)
13 (52%)

0.318
NA
0.312
0.372
0.011
0.765
0.070

147 [135, 163]
24 [4, 59]
46.4 [34.4, 56.5]
53 [20, 77]
20.2 [17, 23.9]
74 [28, 93]
7 (19%)

147 [128, 160]
14 [1, 47]
47.1 [27.4, 72.4]
59 [14, 91]
19.4 [16.6, 27.1]
77 [38, 91]
1 (14%)

147 [135, 163]
23 [3, 55]
46.4 [34.0, 57.3]
54 [18, 77]
20 [17.4, 24.1]
76 [33, 93]
8 (19%)

164 [149, 171]
40 [27, 86]
73.5 [60.4, 90.6]
97 [71, 99]
25.1 [22.9, 36.3]
93 [82, 99]
12 (48%)

0.003
0.033
<0.001
<0.001
<0.001
<0.001
0.014

15 (43%)
11 (31%)
9 (26%)
26 (74%)
19 (53%)

2 (33%)
2 (33%)
2 (33%)
6 (86%)
2 (29%)

17 (41%)
13 (32%)
11 (27%)
32 (76%)
21 (49%)

12 (48%)
10 (40%)
3 (12%)
17 (68%)
15 (60%)

0.409

Renal health
Age at CKD onset, years
Years with CKD
ieGFR at entry, ml/min/1.73 m2
IeGFR < 45 ml/min/1.73 m2
ieGFR change per year, %
ieGFR change per year, ml/min
uPCR at entry, mg/mg creatinine
Proteinuria, uPCR > 2

6.5 [2.5, 11.5]
5.3 [3.4, 7.9]
48 [34, 71]
14 (39%)
−7.4% [−3.1%, −2.9%]
−4.1 [−12.3, −1.7]
1.6 [0.2, 5.5]
15 (43%)

4.5 [3.5, 3.5]
3.7 [2.2, 2.3]
32 [26, 98]
4 (57%)
−2.2% [−14.0%, −14.2%]
−2.5 [−7.8, 5.9]
1.0 [0.1, 1.2]
3 (43%)

Therapy use
Anti-hypertension therapy
ACEi/ARB therapy
Missed ACEi/ARB in last 30 days
Missed ACEi/ARB in last 7 days
Steroid therapy
Immunosuppression therapy

31 (86%)
29 (81%)
7 (19%)
6 (17%)
7 (19%)
17 (47%)

7 (100%)
7 (100%)
1 (14%)
3 (43%)
2 (29%)
5 (71%)

Male
Black race
Age at study entry, years
Low birth weight (<2500 g)
Premature
Small for gestational age
Low birth weight, premature, or
small for gestational age
Height, cm
Height percentile
Weight, kg
Weight percentile
Body mass index, kg/m2
BMI percentile
Obese
Socioeconomic variables
Household income
<$36,000
≥$36,000 and <$75,000
≥$75,000
Maternal education < college
Any public insurance

5.5 [2.5, 11.5]
12.0 [9.5, 12.5]
5.2 [3.3, 7.9]
3.3 [1.1, 4.7]
48 [32, 79]
61 [48, 69]
18 (42%)
6 (24%)
−7.4% [−23.0%, −2.9%] −8.3% [−14.9%, −1.7%]
−4.8 [−12.8, −1.7]
−4.4 [−9.6, −1.1]
1.5 [0.2, 5.5]
0.9 [0.3, 1.8]
18 (43%)
3 (13%)
38 (88%)
36 (84%)
8 (19%)
9 (21%)
9 (21%)
22 (51%)

25 (100%)
22 (88%)
4 (16%)
10 (40%)
8 (32%)
14 (56%)

0.571
0.453
0.004
0.008
0.132
0.190
0.994
0.903
0.330
0.025
0.150
0.735
1.000
0.103
0.387
0.803

BMI, body mass index; CKD, chronic kidney disease; ieGFR, measured or estimated glomerular filtration rate; uPCR, urine protein to creatinine ratio.
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N=
+40%
+30%
+20%
+10%
0%

GFR change per year

-10%

30

5

23

95%

-2.2 %

-7.4 %

75%

-8.9 %

-20%

50%

25%

-30%
-40%
10%

-50%

5%
2.5%

-60%

-70%

Non-AA
APOL1 LR

AA
APOL1 LR

AA
APOL1 HR

FIGURE 2 | Percentile boxplots of longitudinal GFR changes based on individual regression equations, expressed as percent change per year, by
APOL1 risk and race. A total of six non-AA LR participants, two AA LR participants, and two AA HR participants only contributed one GFR measurement and
were not included in this analysis.

group. LDL cholesterol was higher in the HR APOL1 group
(p = 0.047), but no differences in total cholesterol, HDL cholesterol, and triglyceride levels were observed. Higher phosphate
was observed among the LR APOL1 group (p = 0.023), but there
was no difference in intact parathyroid hormone. Children with
HR APOL1 had a higher proportion of CRP values greater than
3 mg/l (33 vs. 15%, p = 0.120).
Table 3 presents odds ratios to describe the associations of
the HR APOL1 profile and selected risk factors and comorbidities. LVH was highly associated with HR APOL1 (OR: 6.2,
95%CI: 1.6, 24.9), as was obesity (OR: 4.7, 95%CI: 1.5, 14.4).
While not statistically significant, HR APOL1 had a higher relative odds of uncontrolled HTN, elevated CRP, and high LDL
cholesterol.

for sex, income, maternal education, insurance status, and 7-day
adherence to antihypertensive therapy. We found no statistical
differences in SES variables between HR and LR APOL1 genotype
groups.
In this comparison, those children with FSGS and HR APOL1
had a significantly older age at CKD onset, and significantly
shorter duration of CKD than those with LR APOL1. Children
with HR APOL1 had a higher GFR at entry although this difference was not statistically significant, p = 0.132. Changes in
GFR over time were similar to APOL1 status (Figure 2). Levels
of uPCR at entry and over time were also similar, although the
HR APOL1 group had a lower proportion with nephrotic range
proteinuria at study entry, p = 0.025.
Table 2 and Table S2A,B in Supplementary Material describe
characteristics related to cardiovascular health stratified by race
and APOL1 risk status among those with an FSGS cause of CKD.
Children with HR APOL1 had higher SBP (p = 0.004), although
SBP percentiles (standardized to the normal population for age,
gender, and height) were not statistically significant (p = 0.132).
No significant differences in DBP were observed. The HR APOL1
children had a higher prevalence of uncontrolled HTN, although
it was not statistically significant. Nearly all children, regardless of
APOL1 status received antihypertensive therapy, the HR APOL1
group had higher (40 vs. 21%) 7-day non-adherence to ACEi/
ARB therapy, p = 0.103 (Table 1). The proportions receiving glucocorticoid and other immunosuppression therapy were similar
by APOL1 risk status.
Increased left ventricular mass index (p = 0.004) and a higher
prevalence of LVH (p = 0.003) were observed in the HR APOL1
Frontiers in Pediatrics | www.frontiersin.org

DISCUSSION
In this cohort of children with FSGS, we demonstrated that AA
children with HR APOL1 genotype were more likely to have FSGS
and to have a later age at FSGS onset, compared to AA children
with LR genotypes. When restricting analysis to children with
FSGS, HR APOL1 was associated with a greater cardiovascular
risk burden, including an increase prevalence of LVH, and obesity, a higher LVMI, BMI, and LDL cholesterol, despite treatment
with antihypertensive therapy and adjustment for indicators of
SES. Notably, other markers of disease severity were not different
between the two groups indicating a potential role for APOL1 in
the etiology of cardiovascular abnormalities.
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TABLE 2 | Cardiovascular and metabolic characteristics among children with FSGS, by race and APOL1 status.
Variable

SBP, mmHg
SBP percentile
DBP, mmHg
DBP percentile
Uncontrolled hypertension
LVMI at V2, g/m2.7
LVH at V2
Total cholesterol, mg/dl
High total cholesterol
HDL cholesterol, mg/dl
Low HDL cholesterol
LDL cholesterol, mg/dl
High LDL cholesterol
Triglycerides, mg/dl
High triglycerides
Hemoglobin, g/dl
Anemia
Calcium, mg/dl
Phosphate (mg/dl)
High phosphate
Calcium × phosphate
iPTH, pg/ml
CRP > 3 mg/l

Non-AA APOL1 LR
n = 36

AA APOL1 LR
n=7

Pooled APOL1 LR
n = 43

APOL1 HR
n = 25

p-Value
(pooled LR vs. HR)

108 [103, 117]
62 [43, 81]
66 [61, 77]
64 [36, 88]
10 (28%)

114 [109, 124]
88 [48, 97]
73 [67, 88]
90 [58, 99]
4 (57%)

109 [103, 119]
64 [45, 88]
69 [61, 79]
68 [37, 92]
14 (33%)

120 [113, 127]
79 [55, 95]
67 [63, 75]
57 [46, 85]
13 (52%)

0.004
0.132
0.889
0.377
0.131

30.0 [26.9, 33.0]
4 (13.8%)
173 [150, 210]
10 (33%)
53 [41, 61]
4 (13%)
90 [71, 120]
5 (17%)
143 [92, 203]
18 (60%)
12.5 [11.3, 13.4]
17 (47%)
9.2 [8.5, 9.6]
4.5 [4.0, 5.1]
6 (17%)
41.7 [37.4, 44.8]
58.0 [35.8, 89.8]
4 (12%)

28.1 [20.7, 28.6]
0 (0%)
186 [174, 205]
2 (40%)
53 [50, 66]
0 (0%)
98 [97, 123]
1 (20%)
118 [93, 160]
3 (60%)
11.7 [10.0, 12.9]
5 (71%)
9.6 [8.0, 9.8]
4.1 [3.7, 6.0]
2 (29%)
41.0 [36.3, 48.0]
144.3 [40.0, 267.8]
2 (29%)

29.6 [26.9, 33.0]
4 (12%)
174 [150, 210]
12 (34%)
53 [41, 63]
4 (11%)
92 [71, 122]
6 (17%)
136 [92, 200]
21 (60%)
12.3 [11.1, 13.3]
22 (51%)
9.2 [8.4, 9.6]
4.4 [4.0, 5.1]
8 (19%)
41.4 [37.0, 45.0]
58.0 [38.0, 95.0]
6 (15%)

40.8 [28.1, 52.9]
9 (45%)
190 [168, 224]
9 (43%)
51 [41, 60]
0 (0%)
112 [101, 145]
7 (33%)
117 [91, 145]
10 (48%)
12.4 [11.9, 13.6]
8 (32%)
9.4 [9.1, 9.7]
4.3 [3.7, 4.7]
0 (0%)
39.9 [34.0, 45.6]
52.0 [39.5, 67.0]
8 (33%)

0.004
0.003
0.222
0.565
0.883
0.286
0.047
0.208
0.441
0.578
0.165
0.139
0.179
0.154
0.023
0.504
0.399
0.120

Median [IQR] or (CI), n (%); p-values based on Fisher’s exact test or Wilcoxon rank-sum test.
SBP, systolic blood pressure; DBP, diastolic blood pressure; LVMI, left ventricular mass index; LVH, left ventricular hypertrophy; V2, visit at 12 months post study enrollment; HDL,
high density lipoprotein; LDL, low density lipoprotein; iPTH, intact parathyroid hormone; CRP, C-reactive protein (high sensitivity or wide range).
Uncontrolled hypertension was defined as SBP or DBP ≥ 95th percentile for age, sex, and height, regardless of a self-reported history of hypertension or receiving antihypertensive
therapy.

particular genotype group or gain in another. This provides
population-based statistical evidence that there is no preferential
loss of HR genotypes between conception and adulthood (2–5).
While our study focused on children who have already been
diagnosed with CKD, we are unable to make inferences about the
general (i.e., non-diseased) pediatric population. Future studies
may wish to characterize the distribution of APOL1 risk alleles in
this group to better understand population risk in children.
Previous studies have established that APOL1 kidney risk
variants are strongly associated with kidney disease among adult
AA; specifically, HIV-associated nephropathy (odds ratio, 29;
95% confidence interval, 13–68) and FSGS (odds ratio, 17; 95%
confidence interval, 11–26) (2–5). In the CKiD cohort, the HR
APOL1 genotype was associated with the glomerular phenotype
in children younger than previously reported; previous studies
have established that APOL1-associated FSGS is characterized by
a tendency to present between ages 15 and 39 years old (7) and in
FSGS-CT with median age 17 years (13, 23) (8). The median age
of FSGS onset among HR children was 12 years in CKiD, which
was older than other LR children with FSGS, a finding previously
reported alongside the NEPTUNE children with nephrotic syndrome (15). Additionally, this study found a higher prevalence of
prematurity among those with HR APOL1 compared to AA and
non-AA children with FSGS, similar to findings with NEPTUNE
that employed a different reference group, suggesting that the
prematurity effect extends to non-AA children.

TABLE 3 | Relative odds of selected risk factors and comorbidities
comparing AA children with FSGS and HR APOL1 to pooled children (i.e.,
non-AA and AA) with FSGS and LR APOL1 based on logistic regression
models.
Unadjusted odds ratios Adjusted odds ratios
(95%CI)
(95%CI)
Left ventricular hypertrophy
Obesity
Uncontrolled hypertension
C-reactive protein > 3 mg/l
High LDL cholesterol

7.97 (1.90, 33.51)
4.04 (1.35, 12.11)
2.24 (0.82, 6.17)
2.74 (0.82, 9.16)
1.34 (0.44, 4.08)

6.22 (1.55, 24.91)
4.65 (1.50, 14.43)
2.54 (0.92, 7.00)
2.41 (0.67, 8.72)
1.22 (0.40, 3.72)

Analyses are unadjusted and adjusted for sex, income less than $30,000, maternal
education less than college, household having any public insurance, and missing a
dose of antihypertensive medication in the past 7 days, as markers of socioeconomic
status. Multiple imputation was used to account for missing data.
LDL, low density lipoprotein.

In children with biopsy confirmed FSGS enrolled in the
FSGS-CT, 72% of self-identified AA subjects and 6% of children
who identified themselves as non-AA had HR APOL1 risk alleles
(8). In the CKiD population, HR APOL1 risk genotype was strongly
associated with both glomerular disease and FSGS. Strikingly, the
prevalence of HR APOL1 among AA children with FSGS was 76%
(25/33), and this was congruent with the 72% observed in the
FSGS-CT. The distribution of APOL1 genotypes observed in the
adult normal population did not differ from Hardy–Weinberg
expectations for genotype distribution; there was no loss of one
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It has been well established that AA children with FSGS
have later onset disease than non-AA children and progress
more rapidly to ESRD (23, 24). In addition, AA children with
nephrotic syndrome have a seven times greater risk of having
been diagnosed with FSGS than Hispanics (Mexicans and other
immigrants from Central America, but not Puerto Ricans and
other Caribbean immigrants) (23), and this has been attributed
to genetic factors. The present analysis suggest that among children with CKD, AA children with HR APOL1 genotype present
with later onset kidney disease, and have a higher prevalence of
cardiovascular and metabolic comorbidities than patients with
LR APOL1 genotype, despite a shorter duration of disease and
the same diagnosis of FSGS. This would suggest that in children
with HR genotypes, FSGS might have a different pathophysiology with the added influence of distinctive environmental factors
(i.e., obesity and potentially birth history, toxin exposure, and/or
additional genetic factors). This in turn may lead to a “vascular/
endothelial” phenotype clinically presenting as uncontrollable
HTN and LVH leading to “enhanced” podocyte injury; in contrast, non-AA primary FSGS may be characterized by a “primary
podocyte” phenotype, earlier onset, and slower CKD progression. It is unclear at present how G1 and G2 alleles may cause
endothelial or podocyte damage, although the APOL1 protein
forms pores in the lysosomal membrane, leading to pathogen
lysis, and a variant APOL1 protein was shown in transgenic mice
to induce direct tissue injury (25).
The role of APOL1 in the adult cardiovascular phenotype
remains controversial. Ito et al. (6) using data from the Jackson
Heart Study (JHS) and Women’s Health Initiative (WHI) demonstrated that the APOL1 kidney risk alleles confer a twofold risk
of cardiovascular events, without significant changes in left ventricular mass, whereas the Systolic Blood Pressure Intervention
Trial (SPRINT) showed the absence of an APOL1 association with
prevalent cardiovascular disease in a non-diabetic adult sample
(26). It is possible that cardiovascular disease–APOL1 interaction
may have an age-dependent relationship pattern, similar to one
described in early- and late-onset forms of Alzheimer disease
associated with apolipoprotein E, epsilon 4 allele, where subjects
at both age spectrum (young-old) seem to be affected by the
disease penetrance (27). It is unknown if similar age-dependent
relationship pattern could also be seen in cardiovascular disease–
APOL1 interaction.
Furth et al. (19) described cardiovascular disease risk factors
in the CKiD cohort and found that only 18% of the cohort exhibited CRP values >3 mg/l (independent of GFR). In our study,
elevated CRP was not statistically different between HR and LR
APOL1 children with FSGS, suggesting that inflammation is not
a driving factor behind LVH. It is possible that differences in LVH
are driven by a combination of APOL1 genotype, underlying
metabolic status, obesity/BMI, HTN, and some other unrecognized socioeconomic or racial variables. Our results showed an
excess of obesity among those with HR APOL1. Since obesity and
metabolic dysregulation are risk factors for both cardiovascular
disease and CKD onset and progression, managing weight prior
to onset in order to prevent or delay disease may be an important clinical consideration. Future studies should seek to clarify
whether the effect of APOL1 on CKD severity is related to obesity
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or whether these two outcomes are independently influenced
by the HR profile. Our finding of increased cardiovascular and
metabolic risks associated with HR genotype in children with
CKD underscores the importance of early detection and need
for more aggressive treatment of obesity, such as early therapy or
adherence support, in this population.
It is also possible that the increased cardiovascular risk in the
HR children is a consequence of the underlying glomerular disease (FSGS) severity and rate of progression. HTN-misattributed
kidney disease in AA has been described in the adult literature
(28). Given the cross-sectional nature of this study, future
research efforts might investigate a large group of AA children
with non-glomerular/congenital kidney disease to investigate
the effect of HR APOL1 on cardiovascular risk, in the absence of
podocyte injury and glomerular damage. Since the vast majority
of HR children in CKiD had a glomerular disease (85%), we were
unable to assess the effect of APOL1 HR on cardiovascular risk
among those with a non-glomerular condition.
This study has several limitations. First, the LR APOL1
subgroup with FSGS was predominantly non-AA. There were
only 7 AA with LR APOL1 compared to 25 AA children with
HR APOL1 and FSGS, thus highlighting the strong association
between HR APOL1 and FSGS among AA children. Since other
forms of glomerular disease among the AA LR APOL1 children,
such as hemolytic uremic syndrome, familial nephritis, or SLE,
were less common than FSGS in AA HR group, we chose to
restrict our analysis to only those with FSGS to determine the
effect of HR APOL1 among those with the same CKD pathology,
which necessitated inclusion of non-AA children with FSGS.
Although a minority of non-AA subjects were genotyped; all
had LR APOL1 status, providing a justification for classifying
non-AA children as LR. It is possible that some children were
misclassified, particularly those of Hispanic ethnicity, although
this misclassification would lead to more conservative estimates.
Ideally, our study would have included a large group of LR and HR
APOL1 AA children with FSGS. As such, we cannot completely
discount genetic (non-APOL1) or metabolic factors related to
race explaining these effects. A related limitation is the potential
confounding effect of race and SES, given the disparate distributions of race between the exposed and unexposed groups. While
several key SES variables were not associated with our exposure,
7-day antihypertensive adherence was related to HR APOL1.
Inverse probability or exposure weights were used to account
for potential differences in SES variables in adjusted analyses,
but there may be other unmeasured SES variables possibly confounding these relationships. The third limitation was the lack
of DNA for analysis in 59 subjects (28 subjects with glomerular
disease), reducing statistical power. We did not characterize
ancestry-informative markers, and therefore, we did not determine the fraction of African ancestry among subjects, although
this information would likely not change any inferences, since
the prevalence of HR APOL1 genotype in this study was nearly
identical to that previously reported (5, 7, 8). Finally, this study
was limited in sample size and may be considered preliminary
data for future research to build upon. These findings need to
be replicated in larger populations in both children and adults.
Despite these limitations, the association of HR APOL1 genotype
7
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with development of glomerular disease, later onset of FSGS and
indications of increased cardiovascular risk among children were
compelling.
In conclusion, this study suggests that APOL1-associated risks
are not restricted to adults only and are present in young children
as well. Indeed, in CKiD, cardiovascular abnormalities were more
common among AA children with HR APOL1. Targeting these
established modifiable comorbidities, especially BMI, obesity,
and HTN, may be a particularly important component in CKD
management to delay ESRD in this HR population.
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